China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
PLANO, Texas, July 28, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference.
Event: Wedbush PacGrow Healthcare Conference
Format: Presentation and One-on-One Meetings
Date: Wednesday, August 16, 2017
Time: 1:20 pm ET
A webcast of the Company’s presentation will be available on the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, COO & CFO (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Zack Kubow (646) 536-7020 [email protected] Brian Johnston (646) 536-7028 [email protected]
